ストックスクリーナーアプリを入手
0.889
7.38%
0.0611
Citius Pharmaceuticals Inc (CTXR) 最新ニュース
Citius Pharmaceuticals Reports Q1 2025 Earnings and Strategic Developments - TipRanks
Citius Pharmaceuticals (CTXR) Receives Continued "Buy" Rating from Analyst | CTXR Stock News - GuruFocus
Citius Pharmaceuticals (CTXR) Receives Continued "Buy" Rating fr - GuruFocus
Citius Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 - GuruFocus
Citius Oncology (CTXR) Seeks Additional Capital for LYMPHIR Laun - GuruFocus
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Citius Pharmaceuticals Reports Fiscal Second Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update - WV News
Citius Pharmaceuticals (CTXR) to Release Quarterly Earnings on Tuesday - Defense World
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™ - Barchart.com
Citius Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - The Malaysian Reserve
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | CTXR Stock News - GuruFocus
Citius Pharmaceuticals Reveals Growth Strategy at Major Jefferies Healthcare Conference - Stock Titan
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Shares Sold by Geode Capital Management LLC - Defense World
Citius Pharmaceuticals stock hits 52-week low at $0.92 - Investing.com
Citius Pharmaceuticals stock hits 52-week low at $0.92 By Investing.com - Investing.com Canada
Citius Pharmaceuticals (CTXR) Price Target Adjusted to $4 Amid S - GuruFocus
Citius Pharmaceuticals stock hits 52-week low at $0.94 By Investing.com - Investing.com South Africa
Citius Pharmaceuticals stock hits 52-week low at $0.94 - Investing.com Australia
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock - Longview News-Journal
Citius Pharmaceuticals stock plummets on $2M registered direct offering of common stock - MSN
Citius Pharmaceuticals stock hits 52-week low at $1.21 - Investing.com
Citius Pharmaceuticals stock hits 52-week low at $1.21 By Investing.com - Investing.com India
Citius Pharma secures $2 million in stock offering By Investing.com - Investing.com South Africa
Citius Pharma secures $2 million in stock offering - Investing.com Australia
Citius Pharmaceuticals announces $2M registered direct offering of common stock - TipRanks
CTXR’s Stock Woes: Down -87.99% in 6 Months, Down -87.99% in Just 5 Days - investchronicle.com
IL-2s gain ground as US market heads for $4 billion by 2034 - The Pharma Letter
Analysts Expect Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) To Breakeven Soon - simplywall.st
Citius Pharmaceuticals stock hits 52-week low at $1.45 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $1.45 - Investing.com India
Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future - simplywall.st
Fisher Asset Management LLC Acquires Shares of 12,800 Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Citius Pharma Advances LYMPHIR Launch Amid Financial Updates - TipRanks
Biotech Alert: Searches spiking for these stocks today - TipRanks
Citius Pharmaceuticals (NASDAQ:CTXR) Given Buy Rating at D. Boral Capital - Defense World
Citius Pharma's LYMPHIR gains permanent J-code for billing - MSN
Citius Pharmaceuticals stock hits 52-week low at $2.43 By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals stock hits 52-week low at $2.43 - Investing.com India
4.23%
3.13%
大文字化:
|
ボリューム (24 時間):